Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab with or without Ibrutinib for untreated advanced follicular lymphoma
2015-001487-19Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ibrutinib in follicular lymphoma (FL) (2 arms), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Complete Response at 24 months. Started Apr 2016; status: completed.
02
Drugs
ibrutinib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2015-001487-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001487-19.